Pfizer Recalls All Lots of Chantix Due to Potential Carcinogen

FRIDAY, Sept. 17, 2021 (HealthDay News) -- Pfizer is expanding the recall of its antismoking drug Chantix (varenicline), the company announced Friday.
The nationwide recall of all Chantix 0.5-mg and 1-mg tablets was prompted because they may contain levels of a nitrosamine, N-nitroso-varenicline, that are at or above levels approved by the U.S. Food and Drug Administration.
Long-term ingestion of N-nitroso-varenicline may be linked to a "theoretical potential increased cancer risk in humans," the company said, adding that no immediate risk to patients taking Chantix exists.
"The health benefits of stopping smoking outweigh the theoretical potential cancer risk from the nitrosamine impurity in varenicline," Pfizer said in its statement.
So far, Pfizer has received no reports of adverse events tied to this recall, the company stated.
Related Posts
Casi 1 de cada 4 pacientes de hospital sufre un evento nocivo durante su estadía
JUEVES, 12 de enero de 2023 (HealthDay News) -- Casi una cuarta parte de las...
When Do Babies Sleep Through the Night?
THURSDAY, April 6, 2023 (HealthDay News) -- Elation and exhaustion often go hand...
Prescriptions Rise for Veterinary Drug for COVID-19 Patients
MONDAY, Aug. 30, 2021 (HealthDay News) -- Despite studies showing that it does...
Eating Red Meat May Up Colorectal Cancer Risk in Black Women
FRIDAY, June 3, 2022 (HealthDay News) -- Unprocessed red meat intake is...